|
|
|
| Research progress on factors related to pregnancy outcome after fertility preservation therapy for endometrial atypical hyperplasia and early endometrial cancer#br# |
| XING Yan HE Yue WU Yumei |
| Department of Gynecologic Oncology, Beijing Obstetrics and Gynecology Hospital, Capital Medical University Beijing Maternal and Child Health Care Hospital, Beijing 100006, China |
|
|
|
Abstract With the change of life style and the delay of average childbearing age, many women were diagnosed with endometrial atypical hyperplasia and early endometrial cancer during their childbearing years. At present, the clinical effect of fertility preservation therapy is confirmed, but only about 50% of patients successfully get pregnant and deliver after complete remission of the disease. Clinical studies have found that age, obesity and overweight, insulin resistance, and diabetes mellitus, endometrial damage and conception mode are important factors affecting pregnancy outcome. This article summarizes the latest research results at home and abroad, discuss, and review the above factors, and provides evidence for patients with endometrial atypical hyperplasia and early endometrial cancer to obtain better pregnancy outcome after fertility preservation therapy.
|
|
|
|
|
|
[1] Jonusiene V，Sasnauskiene A. Notch and Endometrial Cancer [J]. Adv Exp Med Biol，2021，1287：47-57.
[2] Won S，Kim MK，Seong SJ. Fertility-sparing treatment in women with endometrial cancer [J]. Clin Exp Reprod Med，2020，47（4）：237-244.
[3] Brooks RA，Fleming GF，Lastra RR，et al. Current recommendations and recent progress in endometrial cancer [J]. CA Cancer J Clin，2019，69（4）：258-279.
[4] Yang B，Xu Y，Zhu Q，et al. Treatment efficiency of comprehensive hysteroscopic evaluation and lesion resection combined with progestin therapy in young women with endometrial atypical hyperplasia and endometrial cancer [J]. Gynecol Oncol，2019，153（1）：55-62.
[5] Pal N，Broaddus RR，Urbauer DL，et al. Treatment of Low-Risk Endometrial Cancer and Complex Atypical Hyperplasia With the Levonorgestrel-Releasing Intrauterine Device [J]. Obstet Gynecol，2018，131（1）：109-116.
[6] Piatek S，Michalski W，Sobiczewski P，et al. The results of different fertility-sparing treatment modalities and obstetric outcomes in patients with early endometrial cancer and atypical endometrial hyperplasia：Case series of 30 patients and systematic review [J]. Eur J Obstet Gynecol Reprod Biol，2021，263：139-147.
[7] Xu Z，Tian Y，Fu J，et al. Efficacy and prognosis of fertility-preserved hysteroscopic surgery combined with progesterone in the treatment of complex endometrial hyperplasia and early endometrial carcinoma [J]. J BUON，2020， 25（3）：1525-1533.
[8] Steiner AZ，Jukic AM. Impact of female age and nulligravidity on fecundity in an older reproductive age cohort [J]. Fertil Steril，2016，105（6）：1584-1588.
[9] 肖泽睿，鹿群，周蓉，等.子宫内膜非典型增生及子宫内膜癌患者保留生育功能治疗的妊娠结局分析[J].中华妇产科杂志，2020，55（12）：857-864.
[10] Raffone A，Travaglino A，Saccone G，et al. Diabetes Mellitus Is Associated with Occult Cancer in Endometrial Hyperplasia [J]. Pathol Oncol Res，2020，26（3）：1377-1384.
[11] 唐露，马艳萍，陈熙琳，等.胰岛素抵抗对辅助生殖助孕结局影响的研究进展[J].中华生殖与避孕杂志，2021， 41（1）：75-78.
[12] Mu N，Xu T，Gao M，et al. Therapeutic effect of metformin in the treatment of endometrial cancer [J]. Oncol Lett，2020，20（5）：156.
[13] Wang YW，He SJ，FengX，et al. Metformin：a review of its potential indications [J]. Drug Des Devel Ther，2017， 11：2421-2429.
[14] Mitsuhashi A，Habu Y，Kobayashi T，et al. Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients [J]. J Gynecol Oncol，2019， 30（6）：e90.
[15] Yang BY，Gulinazi Y，Du Y，et al. Metformin plus megestrol acetate compared with megestrol acetate alone as fertility-sparing treatment in patients with atypical endometrial hyperplasia and well-differentiated endometrial cancer：a randomised controlled trial [J]. BJOG，2020， 127（7）：848-857.
[16] Acosta-Torres S，Murdock T，Matsuno R，et al. The addition of metformin to progestin therapy in the fertility-sparing treatment of women with atypical hyperplasia / endometrial intraepithelial neoplasia or endometrial cancer：Little impact on response and low live-birth rates [J]. Gynecol Oncol，2020，157（2）：348-356.
[17] Kahn JL，Buckingham L，Koelper NC，et al. Risk factors for atypical hyperplasia and endometrial cancer in the infertility population: a case-control study [J]. F S Rep，2020，2（1）：104-108.
[18] Li M，Guo T，Cui R，et al. Weight control is vital for patients with early-stage endometrial cancer or complex atypical hyperplasia who have received progestin therapy to spare fertility：a systematic review and meta-analysis [J].Cancer Manag Res，2019，11：4005-4021.
[19] Shikeli S，Gowri V，Rawahi TA. Fertility-Sparing Treatment in Young Women with Atypical Endometrial Hyperplasia and Low-Grade Endometrial Cancer：A Tertiary Center Experience [J]. JBRA Assist Reprod，2020，24（4）：466-469.
[20] 黄骁昊，韩素萍，周雪.子宫内膜复杂性不典型增生及早期子宫内膜癌患者保留生育功能的预后研究[J].肿瘤学杂志，2019，25（11）：980-984.
[21] Janda M，Robledo KP，Gebski V，et al. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma：Results of a randomized clinical trial [J]. Gynecol Oncol，2021，161（1）：143-151.
[22] Zhang Y，Li D，Yan Q，et al. Weight Loss Improves Pregnancy and Livebirth Outcomes in Young Women with Early-Stage Endometrial Cancer and Atypical Hyperplasia [J]. Cancer Manag Res，2021，13：5711-5722.
[23] Kim MK，Seong SJ. Conservative treatment for atypical endometrial hyperplasia：what is the most effective therapeutic method？[J]. J Gynecol Oncol，2014，25（3）：164-165.
[24] Fan Y，Li X，Wang J，et al. Analysis of pregnancy-associated factors after fertility-sparing therapy in young women with early stage endometrial cancer or atypical endometrial hyperplasia [J]. Reprod Biol Endocrinol，2021，19（1）：118.
[25] Inoue O，Hamatani T，Susumu N，et al. Factors affecting pregnancy outcomes in young women treated with fertility-preserving therapy for well-differentiated endometrial cancer or atypical endometrial hyperplasia [J]. Reprod Biol Endocrinol，2016，14：2.
[26] Hosseinzadeh P，Evans MB. Thin endometrial lining in single euploid embryo transfers：should we be concerned about adverse live birth outcomes？[J]. F S Rep，2021，2（2）：140-141.
[27] Liu KE，Hartman M，Hartman A，et al. The impact of a thin endometrial lining on fresh and frozen-thaw IVF outcomes：an analysis of over 40000 embryo transfers [J]. Hum Reprod，2018，33（10）：1883-1888.
[28] Novikova OV，Nosov VB，Panov VA，et al. Live births and maintenance with levonorgestrel IUD improve disease-free survival after fertility-sparing treatment of atypical hyperplasia and early endometrial cancer [J]. Gynecol Oncol，2021，161（1）：152-159.
[29] Kou L，Jiang X，Xiao S，et al. Therapeutic options and drug delivery strategies for the prevention of intrauterine adhesions [J]. J Control Release，2020，318：25-37.
[30] Zhang G，Wang Y，Liang XD，et al. Microscale endometrial sampling biopsy in detecting endometrial cancer and atypical hyperplasia in a population of 1551 women：a comparative study with hysteroscopic endometrial biopsy [J]. Chin Med J（Engl），2020，134（2）：193-199.
[31] Wang L，Luo X，Wang Q，et al. Fertility-preserving treatment outcome in endometrial cancer or atypical hyperplasia patients with polycystic ovary syndrome [J]. J Gynecol Oncol，2021，32（5）：e70.
[32] Masciullo V，Trivellizzi N，Zannoni G，et al. Prognostic impact of hysteroscopic resection of endometrial atypical hyperplasia-endometrioid intraepithelial neoplasia and early-stage cancer in combination with megestrolacetate [J]. Am J Obstet Gynecol，2021，224（4）：408-410.
[33] Yamagami W，Susumu N，Makabe T，et al. Is repeated high-dose medroxyprogesterone acetate（MPA）therapy permissible for patients with early stage endometrial cancer or atypical endometrial hyperplasia who desire preserving fertility？[J]. J Gynecol Oncol，2018，29（2）：e21.
[34] Vaugon M，Peigné M，Phelippeau J，et al. IVF impact on the risk of recurrence of endometrial adenocarcinoma after fertility-sparing management [J]. Reprod Biomed Online，2021，16（21）：291.
[35] Diakosavvas M，Fasoulakis Z，Ntounis T，et al. A Potential Pathogenic Link Between Cancer of Female Reproductive System and Infertile Women Treated With Assisted Reproduction Techniques [J]. In Vivo，2021，35（3）：1393-1399.
[36] 肖亚玲，孙正怡，王雪，等.早期子宫内膜癌和子宫内膜非典型增生患者保守治疗后的IVF-ET治疗结局[J].生殖医学杂志，2021，30（1）：1-6. |
|
|
|
